Abstract:Qiuning Wang, 1, &ast Weiying Chen, 2, &ast Xuefeng Yang, 3 Ying Song, 4 Xiaowei Sun, 5 Guizhou Tao, 6 Hong Wang, 7 Nan Zhao, 7 Yue Huang, 1 Erqing Chai, 8 Futian Tang 9 1 Department of Pharmacology, Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 2 Department of Drug Quality Analysis, Jiuquan Drug Inspection and Testing Center, Jiuquan, Gansu Province, People's Republic of China; 3 Department of Physiology, Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 4 Cardiovascular Laboratory, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 5 Department of Neurosurgery, China Resources Liaojian Group, General Hospital of Fuxin Mining Group (10th Clinical College of China Medical University), Fuxin, Liaoning Province, People's Republic of China; 6 Internal Medicine-Cardiovascular Department, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 7 Allergy and Clinical Immunology Center, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, People's Republic of China; 8 Neurointerventional Department, Emergency General Hospital, Beijing, People's Republic of China; 9 Department of Cardiovascular Disease and Key Laboratory of Digestive System Tumor of Gansu Province, Lanzhou University Second Hospital, Lanzhou, Gansu Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Futian Tang, Department of Cardiovascular Disease and Key Laboratory of Digestive System Tumor of Gansu Province, Lanzhou University Second Hospital, Lanzhou, Gansu Province, People's Republic of China, Email Erqing Chai, Neurointerventional Department, Emergency General Hospital, Beijing, People's Republic of China, Email Introduction: Astragaloside IV (AS-IV) is one of the main active components isolated from the traditional Chinese medicinal herb, Astragalus membranaceus . The present study was designed to investigate whether the regulation of microRNA-1 (miR-1)-mediated inflammation and autophagy contributes to the protective effect of AS-IV against cardiac dysfunction in rats treated with lipopolysaccharides (LPS). Methods: Animal model of cardiac dysfunction in rats or cellular model of injured H9c2 heart cell line was established by using LPS. Echocardiography, electron microscopy, enzyme-linked immunosorbent assay, immunofluorescence, quantitative RT-PCR, and Western blotting were used to determine the cardiac function and expression of inflammation- and autophagy-related proteins at both the mRNA and protein levels. Results: LPS caused cardiac dysfunction in rats or injury in H9c2 cells and induced inflammation and autophagy. Compared with LPS treatment, AS-IV treatment attenuated cardiac dysfunction or cell injury, accompanied by inhibition of inflammation and autophagy. However, the miR-1 mimics partly abolished the effects of AS-IV. In addition, the effect of the miR-1 inhibitor was similar to that of AS-IV in the LPS model. Further analyses showed that AS-IV treatment decreased the mRNA expression of miR-1 in the heart tissue of rats and H9c2 cells treated with LPS. Conclusion: These results suggest that AS-IV attenuated cardiac dysfunction caused by LPS by inhibiting miR-1-mediated inflammation and autophagy, thereby providing a novel mechanism for the protection against cardiac diseases. Keywords: lipopolysaccharides, astragaloside IV, cardiac dysfunction, inflammation, autophagy, miRNA-1 Astragali Radix is prepared from the roots of Astragalus membranaceus (Fisch.) Bunge. 1 As a kind of traditional Chinese medicine, Astragali Radix has a wide range of pharmacological effects, especially on cardiovascular diseases, such as coronary heart disease, 2 heart failure, 3 viral myocarditis, 4 and hypertension. 5 Astragaloside IV (AS-IV), one of the main active ingredients in A. membranaceus , exerts various protective effects against cardiovascular diseases, such as preventing the endothelial dysfunction of the aortas in streptozotocin-induced diabetic mice, 6 ameliorating lead-related cognitive impairments in mice, 7 attenuating hypoxia-induced pulmonary vascular remodeling, 8 and restoring myocardial infarction-induced cardiac dysfunction. 9 Many studies have shown that several mechanisms contribute to the protective effects -Abstract Truncated-

Astragaloside protects myocardial cells from apoptosis through suppression of the TLR4/NF-κB signaling pathway

Astragaloside IV protects cardiomyocytes from hypoxic injury by regulating endoplasmic reticulum stress via eIF2α/CHOP signaling pathway

Astragaloside Iv from Astragalus Membranaceus Shows Cardioprotection During Myocardial Ischemia in Vivo and in Vitro

Astragaloside IV-targeting miRNA-1 attenuates lipopolysaccharide-induced cardiac dysfunction in rats through inhibition of apoptosis and autophagy

Astragaloside IV protects diabetic cardiomyopathy against inflammation and apoptosis via regulating TLR4/MyD88/NF-κB signaling pathway

Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways

Astragaloside IV Inhibits NLRP3 Inflammasome-Mediated Pyroptosis via Activation of Nrf-2/HO-1 Signaling Pathway and Protects against Doxorubicin-Induced Cardiac Dysfunction

Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway

Astragaloside Iv Attenuates Hypoxia-Induced Cardiomyocyte Damage in Rats by Upregulating Superoxide Dismutase-1 Levels

Astragaloside IV Inhibits Doxorubicin-Induced Cardiomyocyte Apoptosis Mediated by Mitochondrial Apoptotic Pathway Via Activating the PI3K/Akt Pathway.

Study on Protective Effect and Mechanism of Astragaloside Ⅳ on D-galactose-induced Primary Cardiomyocytes Apoptosis

Astragaloside IV protects cardiomyocytes against hypoxia injury via HIF-1α and the JAK2/STAT3 pathway

Effects of astragalus polysaccharide on cell injury and mitochondrial pathway apoptosis in the hypoxia reoxygenation of myocardial cells

Astragaloside IV Inhibits Cardiac Fibrosis Via Mir-135A-trpm7-tgf-β/smads Pathway.

Protective Effects of Astragalosides on Apoptosis of Myocardial Cells Induced by Hydrogen Peroxide

Astragaloside IV inhibits proliferation and promotes apoptosis in rat vascular smooth muscle cells under high glucose concentration in vitro.

Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway

Extracts from Astragalus Membranaceus Limit Myocardial Cell Death and Improve Cardiac Function in a Rat Model of Myocardial Ischemia.

Astragaloside IV intervenes multi-regulatory cell death forms against doxorubicin-induced cardiotoxicity by regulating AMPKα2 pathway

Astragaloside IV Reduces OxLDL-Induced BNP Overexpression by Regulating HDAC

Inhibition of miRNA-1-Mediated Inflammation and Autophagy by Astragaloside IV Improves Lipopolysaccharide-Induced Cardiac Dysfunction in Rats